Abstracts Archive - Page 983 of 2607 - ACR Meeting Abstracts

Abstract Number: 135 • 2020 Pediatric Rheumatology Symposium
Use of Intravenous Pamidronate in Pediatric Leukemia Patients with Osteonecrosis Results in Reduced Pain and May Halt Osteonecrosis Progression
Paivi Miettunen¹, Chloe Stephenson ¹, Seemab Haider ¹, Seamus Stephenson ², Vijay Moorjani ² and Rondald Anderson ², ¹University of Calgary, Calgary, Alberta, Canada, ²University of Calgary, Calgary, Canada
Background/Purpose: Osteonecrosis has emerged as debilitating complication of acute pediatric lymphoblastic leukemia (pALL), with severe pain and poor functional outcome. Patients with ON of weight…
Abstract Number: 136 • 2020 Pediatric Rheumatology Symposium
Prevalence of Paradoxical Psoriasis After Exposure to Tumor Necrosis Factor Inhibitors (TNFi) in Children from a Single Tertiary Center
Sarah Kodama¹, Deepti Gupta ², Erin Sullivan ³ and Yongdong Zhao ⁴, ¹School of Medicine, Virginia Commonwealth University, Richmond, ²Pediatric Dermatology, School of Medicine, University of Washington, Seattle, ³Seattle Children's Research Institute, Seattle, ⁴University of Washington, Seattle
Background/Purpose: Paradoxical psoriasis after exposure to tumor necrosis factor inhibitors (TNFi) has been increasingly reported in the adult population. Systematic studies in pediatric population are…
Abstract Number: 137 • 2020 Pediatric Rheumatology Symposium
Measuring Decision Conflict in Parents of Children with Juvenile Idiopathic Arthritis When Making the Decision to Begin Disease Modifying Anti-Rheumatic Drugs or Biologic Agents
Chelsea DeCoste¹, Suzanne Ramsey ², Adam Huber ³, Bianca Lang ⁴ and Elizabeth Stringer ², ¹The Hospital for Sick Children, Toronto, Canada, ²IWK Health Centre, Halifax, Canada, ³IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, ⁴Dalhousie University - Halifax, Halifax, Canada
Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) and biologic agents are routinely used in the treatment of JIA and JIA-associated uveitis (JIA-AU). Parents are often fearful, however,…
Abstract Number: 138 • 2020 Pediatric Rheumatology Symposium
Serious Infection Risk in Pediatric Patients with Low Immunoglobulin Levels Following Rituximab Treatment for Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
Simone Melega ¹, Paul Brogan², Gavin Cleary ³, Aimee Hersh ⁴, Ozgur Kasapcopur ⁵, Satyapal Rangaraj ⁶, Rae Yeung ⁷, Andrew Zeft ⁸, Jennifer Cooper ⁹, Pooneh Pordeli ¹⁰, Petra Kirchner ¹¹ and Patricia Lehane ¹², ¹F. Hoffmann-La Roche, Ltd., Basel, Switzerland, ²UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ³Alder Hey Children's Hospital, Liverpool, United Kingdom, ⁴University of Utah Primary Children's Hospital, Salt Lake City, ⁵Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Cerrahpasa, Turkey, ⁶Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, ⁷The Hospital for Sick Children, Toronto, Canada, ⁸The Cleveland Clinic - Center for Pediatric Rheumatology & Immunology, Cleveland, Ohio, ⁹University of Colorado, Children's Hospital Colorado, Denver, ¹⁰F. Hoffmann-La Roche, Ltd., Mississauga, Canada, ¹¹F. Hoffmann-La Roche Ltd., Birsfelden, Switzerland, ¹²Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: Low immunoglobulin (Ig) levels can occur after rituximab treatment, but the clinical significance is not completely understood. Not all patients (pts) who develop low…
Abstract Number: 139 • 2020 Pediatric Rheumatology Symposium
Ongoing Disease Activity in Juvenile Idiopathic Arthritis (JIA) 18 Years After Disease Onset: A Population-based Nordic Study
Mia Glerup¹, Ellen D Arnstad ², Veronika Rypdal ³, Suvi Peltoniemi ⁴, Kristiina Aalto ⁵, Marite Rygg ⁶, Susan Nielsen ⁷, Anders Fasth ⁸, Lillemor Berntson ⁹, Ellen Nordal ³ and Troels Herlin ¹⁰, ¹Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, ²Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology, and Department of Pediatrics, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway., Tromheim, Norway, ³Department of Pediatrics, University Hospital of North Norway, and Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway., Tromsø, Norway, ⁴Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., Helsinki, Finland, ⁵Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., HUS, Finland, ⁶Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology and Department of Pediatrics, St. Olavs Hospital, Trondheim, Norway., Trondheim, Norway, ⁷Department of Pediatrics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Copenhagen, Denmark, ⁸Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Gothenburg, Sweden, ⁹Department of Womens and Childrens Health, Uppsala University, Uppsala, Sweden., Uppsala, Sweden, ¹⁰Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark., Aarhus N, Denmark
Background/Purpose: Previously, we showed that ILAR JIA categories defined at disease onset change considerably during the first 8 years of disease course. Whether achieved remission…
Abstract Number: 140 • 2020 Pediatric Rheumatology Symposium
Serum Biomarkers in a German Cohort of Patients with Systemic Juvenile Idiopathic Arthritis and Their Relationship to Response to Interleukin-1 Blockade
Claas Hinze¹, Tanja Hinze ², Helmut Wittkowski ¹, Christoph Kessel ¹, Sabrina Fuehner ¹ and Dirk Foell ¹, ¹University Hospital Muenster, Muenster, Nordrhein-Westfalen, Germany, ²Muenster, Nordrhein-Westfalen, Germany
Background/Purpose: Most, but not all, patients with systemic juvenile idiopathic arthritis (systemic JIA) respond to therapy with interleukin (IL)-1 blocking agents but predictive factors have…
Abstract Number: 141 • 2020 Pediatric Rheumatology Symposium
Cyclophosphamide Use in Treatment of Refractory Kawasaki Disease: A Single Center Case Series of 10 Patients and Literature Review
Olha Halyabar¹, Mary Beth Son ², Margaret Chang ³ and Robert Sundel ¹, ¹Children's Hospital/Boston Medical Center, Boston, ²Boston Children's Hospital, Boston, Massachusetts, ³Boston Children's Hospital, Boston
Background/Purpose: Intravenous immunoglobulin (IVIG) effectively treats vasculitis of the coronary arteries in the large majority of Kawasaki Disease (KD) patients. However, approximately 25% of patients…
Abstract Number: 142 • 2020 Pediatric Rheumatology Symposium
WITHDRAWN
Abstract Number: 143 • 2020 Pediatric Rheumatology Symposium
Immunological Profiles Following Treatment with Rituximab in Autoimmune Disease
Laura Cannon ¹, Stephanie Johannes¹ and Jeffrey Dvergsten ², ¹Duke University, Durham, ²Duke University Hospital, Hillsborough
Background/Purpose: Autoimmune diseases, including systemic lupus erythematosus (SLE), juvenile dermatomyositis (JDM), and Autoimmune Encephallitis (AE) arise due to dysregulation of the immune system and a…
Abstract Number: 144 • 2020 Pediatric Rheumatology Symposium
Failure of Methotrexate Monotherapy and Subsequent Response to Tumor Necrosis Factor Inhibitors in Pediatric Non-Infectious Uveitis
Ashley Cooper¹, Basak Can Ermerak ², Katie Keck ³ and Erin Stahl ¹, ¹Children's Mercy Kansas City, Kansas City, ²University Hospitals Cleveland Medical Center, Cleveland, ³Palmetto Health USC Medical Group, Columbia
Background/Purpose: Pediatric non-infectious uveitis is often treated with systemic immunomodulators in a step-wise fashion, with methotrexate (MTX) followed by tumor necrosis factor alpha inhibitors (TNFi)…
Abstract Number: 145 • 2020 Pediatric Rheumatology Symposium
Anti-Citrullinated Protein Antibodies (ACPA) and Bony Erosions in Polyarticular JIA
Saumya Joshi¹, Yujuan Zhang ¹ and Trevor Davis ², ¹Tufts Medical Center, Boston, Massachusetts, ²Norwell, Massachusetts
Background/Purpose: Despite being a well-established biomarker for classification of aggressive bony disease in adults with RA, ACPA have not yet been described in the ILAR…
Abstract Number: 146 • 2020 Pediatric Rheumatology Symposium
Immersive Virtual Reality for Management of Amplified Musculoskeletal Pain Syndrome in Adolescents: A Pilot Randomized Controlled Trial
Saumya Joshi¹, Yujuan Zhang ¹, Lori Lyn Price ², Trevor Davis ³ and Raveendhara Bannuru ¹, ¹Tufts Medical Center, Boston, Massachusetts, ²Boston, Massachusetts, ³Norwell, Massachusetts
Background/Purpose: Amplified Musculoskeletal Pain Syndrome (AMPS), a chronic pain syndrome with excessive musculoskeletal pain without a primary organic etiology, has a high prevalence in adolescents.…
Abstract Number: 147 • 2020 Pediatric Rheumatology Symposium
Familial Clustering of Immune-mediated Diseases in Children with Abrupt-onset OCD
Avis Chan ¹, Tiffany Phu ¹, Bahare Farhadian ², Theresa Willett ³, Melissa Silverman ¹, Paula Tran ¹, Margo Thienemann ³ and Jennifer Frankovich⁴, ¹Stanford University School of Medicine, Palo Alto, ²Stanford Immune Behavioral Health Clinic and PANS Research Program at Lucile Packard Children's Hospital, Palo Alto, ³Stanford University School of Medicine, Palo Alto, California, ⁴Stanford
Background/Purpose: Recent epidemiologic studies have reported increased rates of immune-mediated comorbidities among first-degree relatives of patients with OCD and tic disorders.(Mataix-Cols et al., Mol Psychiatry…
Abstract Number: 148 • 2020 Pediatric Rheumatology Symposium
Chronic Fatigue Symptoms in Children with Abrupt Early-onset OCD And/or PANS
Avis Chan ¹, Angeline Truong ², Bahare Farhadian ³, Theresa Willett ², Melissa Silverman ¹, Paula Tran ¹, Margo Thienemann ² and Jennifer Frankovich⁴, ¹Stanford University School of Medicine, Palo Alto, ²Stanford University School of Medicine, Palo Alto, California, ³Stanford Immune Behavioral Health Clinic and PANS Research Program at Lucile Packard Children's Hospital, Palo Alto, ⁴Stanford
Background/Purpose: Chronic Fatigue Syndrome (CFS)/Myalgic encephalomyelitis (ME) affects roughly 2.5 million people in the United States, and is challenging both in diagnosis and treatment. Many…
Abstract Number: 149 • 2020 Pediatric Rheumatology Symposium
Low C4 Copy Number of Total C4 Gene, C4B Gene and C4BL Gene in Children with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)
Agnieszka Kalinowski ¹, Justin Lee ², Haley Hedlin ², Reenal Pattini ², Hanna Ollila ², Emmanuel Mignot ¹, Douglas Levinson ², Susan Swedo ³, Tanya Murphy ⁴, Avis Chan ⁵, Margo Thienemann ¹, Alexander Urban ² and Jennifer Frankovich⁶, ¹Stanford University School of Medicine, Palo Alto, California, ²Stanford University, Palo Alto, California, ³National Institute of Mental Health, Bethesda, Maryland, ⁴University of South Florida, Tampa, Florida, ⁵Stanford University School of Medicine, Palo Alto, ⁶Stanford
Background/Purpose: Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) is characterized by sudden-onset OCD and additional neuropsychiatric symptoms. Imaging studies point to inflammation in the basal ganglia as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].